Valneva Austria
Organization
Trials
Phase 1, Completed, 150 people, Mar 28, 2024
Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43
Phase 2/3, Completed, 803 people, Mar 26, 2012
Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients
Phase 2, Completed, 400 people, Apr 6, 2009
Sources: clinicaltrials.gov